Clinical trials: Locally Advanced Head and Neck Cancer
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of…
- Trial name
- NCT07437898
- Testing
- Adebrelimab, chemotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Hospital of Putian University
Nasopharyngeal Carcinoma
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT05097209
- Testing
- Camrelizumab, Gemcitabine, Induction Cisplatin
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Wei Jiang
Esophageal Cancer
Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601692
- Testing
- cisplatin, docetaxel, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
The purpose of this clinical research study is to learn if a paclitaxel-cisplatin combination regimen given in the neoadjuvant setting is active in locally advanced head and neck cancer.
- Trial name
- NCT00337532
- Testing
- Paclitaxel, cisplatin
- Where
- 2 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Thyroid Cancer
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
This study is a multicenter observational study. Patients receive neoadjuvant therapy with RET inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment.
- Trial name
- NCT06530316
- Testing
- RET Inhibitor, Surgery
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Esophageal Cancer
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
This study is a randomized, multi-center, open-label, phase II study of a PD-1 inhibitor (INCMGA00012) versus observation as consolidation therapy after definitive concurrent chemoradiotherapy in patients with locally advanced…
- Trial name
- RHAPSODY (NCT04494009)
- Testing
- INCMGA00012
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Head and Neck Cancer
Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients
The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation…
- Trial name
- SYMTECH01 (NCT06385587)
- Testing
- Oleena
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Aptar Digital Health
Oral Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial
The trial is a study conducted to evaluate the safety, tolerability and PK characteristics of Carrimycin tablet and measure its anti-tumor efficacy initially in the treatment of patients with locally advanced, recurrent, or…
- Trial name
- NCT04413214
- Testing
- Carrimycin
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cancer-related Fatigue, Survival
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative…
- Conditions
- Cancer-related Fatigue, Survival, Tumor, Esophageal
- Trial name
- NCT03611712
- Testing
- Astragalus Polysaccharides 500 mg
- Where
- 4 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- PhytoHealth Corporation
Squamous Cell Carcinoma of the Head and Neck
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
- Trial name
- NCT03880396
- Testing
- hypofractionated Rth with platinol
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Assiut University
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Cancer
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
This is an open label, single arm Phase II study of induction chemotherapy followed by concurrent chemo-radiotherapy in patients with locally advanced head and neck squamous cell cancer (HNSCC) using monoclonal antibody…
- Trial name
- NCT01326923
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Nasopharyngeal Carcinoma
Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Researchers conduct the clinical trial (gemcitabine combined with cisplatin induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine for locally advanced nasopharyngeal carcinoma) to evaluate the safety…
- Trial name
- NCT04522050
- Testing
- Gemcitabine combined with cisplatin induction chemotherapy, concurrent chemoradiotherapy with gemcitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Head and Neck Neoplasms
Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
The goal of this study is to test, in a randomized controlled trial among head and neck cancer patients, the short and longer term effects of the MPACT (Maintaining Physical Activity during Cancer Treatment) program (infused with…
- Trial name
- NCT02485470
- Testing
- MPACT
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer
Head and Neck Early Relapse Detection Study (HERD)
Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with an annual incidence of 12000 cases in the UK alone. More than 60% of cases are diagnosed at the locally advanced stage.
- Trial name
- HERD (NCT05097625)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- University College, London
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of sintilimab combined with chemotherapy, followed by sequential concurrent chemoradiotherapy as conversion therapy, in…
- Trial name
- NCT06709417
- Testing
- Sintilimab, Chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase I/II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have locally advanced, recurrent, or metastatic head and neck cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00055770
- Testing
- erlotinib hydrochloride, docetaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)